Amgen Medications - Search News

Amgen, Obesity and FDA

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

Bloomberg on MSN · 1d

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs.

FierceBiotech · 1d

Amgen's early-stage obesity asset slapped with FDA hold

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial

Amgen Inc. Q4 Profit Decreases

Reuters · 1d

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

BioSpace · 21h

Pipeline Problems Mar Amgen’s Q4 Beat

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.

Business Insider · 1d

Amgen Inc. Q4 Profit Decreases, But Beats Estimates

Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.

FiercePharma18h

With recent launches and more to come, Amgen's biosimilar business is trending up

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

STAT19h

Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

15h

Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

1don MSN

Amgen Surpasses Q4 Earnings Forecasts

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

2don MSN

Amgen's SWOT analysis: stock outlook amid obesity drug race

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

The Motley Fool: An inside look at Amgen’s fall

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

4don MSN

Open Source: Amgen CEO credited new NC factory to Trump tax cuts. Is he right?

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results